{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:58:41Z","timestamp":1768287521559,"version":"3.49.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Obesity is a global epidemic and people living with HIV (PLWH) are showing similar obesity trends to those in the general population. Obesity is manifested by several physiological features that can alter volume of distribution, elimination and metabolism of various medications including ART. Some drugs are increasingly prone to pharmacokinetic alteration during obesity depending on their physicochemical properties and clearance mechanism. These considerations raise concerns of hampered efficacy, development of resistance or increased toxicity of ART in PLWH. Here, we summarize available literature on the exposure and antiviral outcomes of currently available antiretroviral drugs in the context of obesity and provide a panel of recommendations for the clinical management and follow-up in this growing patient population.<\/jats:p>","DOI":"10.1093\/jac\/dkac368","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T17:18:03Z","timestamp":1667409483000},"page":"3215-3220","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of modern antiretroviral therapy in obese individuals living with HIV"],"prefix":"10.1093","volume":"77","author":[{"given":"L","family":"Zino","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Radboud Institute for Health Sciences, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Stalenhoef","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, OLVG Hospital , Amsterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0389-9934","authenticated-orcid":false,"given":"A","family":"Colbers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Radboud Institute for Health Sciences, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D M","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Radboud Institute for Health Sciences, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"2022122818212263300_dkac368-B1","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1097\/QAD.0000000000003092","article-title":"Weight gain stopping\/switch rules for antiretroviral clinical trials","volume":"35","author":"Venter","year":"2021","journal-title":"AIDS"},{"key":"2022122818212263300_dkac368-B2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/hiv.12857","article-title":"Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross-sectional analysis","volume":"21","author":"Savinelli","year":"2020","journal-title":"HIV Med"},{"key":"2022122818212263300_dkac368-B3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.therap.2017.08.007","article-title":"Effect of body weight and composition on efavirenz, atazanavir or darunavir concentration","volume":"73","author":"Lloret-Linares","year":"2018","journal-title":"Therapie"},{"key":"2022122818212263300_dkac368-B4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/clpt.2011.104","article-title":"Implications of obesity for drug therapy: limitations and challenges","volume":"90","author":"Jain","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2022122818212263300_dkac368-B5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2022122818212263300_dkac368-B6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","article-title":"Effects of obesity on pharmacokinetics implications for drug therapy","volume":"39","author":"Cheymol","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"2022122818212263300_dkac368-B7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/01.CIR.103.6.820","article-title":"Relations of stroke volume and cardiac output to body composition: the strong heart study","volume":"103","author":"Collis","year":"2001","journal-title":"Circulation"},{"key":"2022122818212263300_dkac368-B8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-198409020-00005","article-title":"The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam","volume":"9","author":"Abernethy","year":"1984","journal-title":"Clin Pharmacokinet"},{"key":"2022122818212263300_dkac368-B9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/106002809502900902","article-title":"Carbamazepine pharmacokinetics in obese and lean subjects","volume":"29","author":"Caraco","year":"1995","journal-title":"Ann Pharmacother"},{"key":"2022122818212263300_dkac368-B10","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1007\/s00394-020-02421-y","article-title":"The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies","volume":"60","author":"Zarezadeh","year":"2021","journal-title":"Eur J Nutr"},{"key":"2022122818212263300_dkac368-B11","doi-asserted-by":"crossref","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment","volume":"215","author":"Stanke-Labesque","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2022122818212263300_dkac368-B12","doi-asserted-by":"crossref","first-page":"e012241","DOI":"10.1161\/JAHA.119.012241","article-title":"HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database","volume":"8","author":"Alonso","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022122818212263300_dkac368-B13","doi-asserted-by":"crossref","first-page":"e0252320","DOI":"10.1371\/journal.pone.0252320","article-title":"An observational study of the prevalence of metabolic syndrome in treatment-experienced people living with HIV in Singapore","volume":"16","author":"Ang","year":"2021","journal-title":"PLoS One"},{"key":"2022122818212263300_dkac368-B14","author":"CDC"},{"key":"2022122818212263300_dkac368-B15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3851\/IMP2107","article-title":"Efavirenz in an obese HIV-infected patient\u2013a report and an in vitro-in vivo extrapolation model indicate risk of underdosing","volume":"17","author":"de Roche","year":"2012","journal-title":"Antivir Ther"},{"key":"2022122818212263300_dkac368-B16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/mp900036s","article-title":"Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys","volume":"6","author":"Durand-Gasselin","year":"2009","journal-title":"Mol Pharm"},{"key":"2022122818212263300_dkac368-B17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.orcp.2016.06.004","article-title":"Tenofovir pharmacokinetic after sleeve-gastrectomy in four severely obese patients living with HIV","volume":"11","author":"Muzard","year":"2017","journal-title":"Obes Res Clin Pract"},{"key":"2022122818212263300_dkac368-B18","first-page":"1137","article-title":"Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study","volume":"72","author":"Madelain","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022122818212263300_dkac368-B19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.clpt.6100269","article-title":"The effect of lopinavir\/ritonavir on the renal clearance of tenofovir in HIV-infected patients","volume":"83","author":"Kiser","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"2022122818212263300_dkac368-B20","first-page":"1315","article-title":"Pharmacokinetics of tenofovir alafenamide fumarate and tenofovir in the Chinese people: effects of non-genetic factors and genetic variations","volume":"14","author":"Li","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"key":"2022122818212263300_dkac368-B21","author":"Berton"},{"key":"2022122818212263300_dkac368-B22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijantimicag.2016.03.017","article-title":"Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy","volume":"47","author":"Orrell","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2022122818212263300_dkac368-B23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2125.2003.02020.x","article-title":"Therapeutic drug monitoring of lopinavir\/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor","volume":"57","author":"Solas","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"2022122818212263300_dkac368-B24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1097\/00002030-200212060-00006","article-title":"HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy","volume":"16","author":"Dupin","year":"2002","journal-title":"AIDS"},{"key":"2022122818212263300_dkac368-B25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication","volume":"13","author":"St\u00f6hr","year":"2008","journal-title":"Antivir Ther"},{"key":"2022122818212263300_dkac368-B26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"2022122818212263300_dkac368-B27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/QAD.0000000000000530","article-title":"Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults","volume":"29","author":"Marzolini","year":"2015","journal-title":"AIDS"},{"key":"2022122818212263300_dkac368-B28","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1007\/s11095-015-1752-9","article-title":"The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery","volume":"32","author":"Brill","year":"2015","journal-title":"Pharm Res"},{"key":"2022122818212263300_dkac368-B29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"2022122818212263300_dkac368-B30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2022122818212263300_dkac368-B31","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1128\/AAC.06407-11","article-title":"Divalent metals and pH alter raltegravir disposition in vitro","volume":"56","author":"Moss","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022122818212263300_dkac368-B32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.surg.2015.04.034","article-title":"Gastroesophageal reflux disease in the obese: pathophysiology and treatment","volume":"159","author":"Nadaleto","year":"2016","journal-title":"Surgery"},{"key":"2022122818212263300_dkac368-B33","doi-asserted-by":"crossref","first-page":"S865","DOI":"10.1093\/ofid\/ofz360.2173","article-title":"Pharmacokinetics of cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) injectables in HIV-infected individuals through 48 weeks in the FLAIR and ATLAS phase 3 studies","volume":"6","author":"Patel","year":"2019","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/12\/3215\/48439622\/dkac368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/12\/3215\/48439622\/dkac368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T21:34:38Z","timestamp":1672263278000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/12\/3215\/6794062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,11,2]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac368","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,11,2]]}}}